Key result
Oral GKT136901 attenuates structural remodeling, diastolic dysfunction, and hypertrophy in Ang II-infused mice.
Why the study?
Shared mechanisms between atrial fibrillation and HFpEF remain unclear, and Pitx2 haploinsufficiency may increase susceptibility to HFpEF-like remodeling.
Does oral GKT136901 improve HFpEF-like structural remodeling, diastolic function, and functional capacity in a Pitx2 haploinsufficiency mouse model treated with angiotensin II?
RCT
randomized
Does oral GKT136901 improve HFpEF-like structural remodeling, diastolic function, and functional capacity in a Pitx2 haploinsufficiency mouse model treated with angiotensin II?
Inhibition of Nox4 with GKT136901 attenuates HFpEF-like structural and hemodynamic remodeling in a Pitx2 haploinsufficiency genetic model, linking redox signaling to AF-HFpEF susceptibility.
Answers are grounded in this paper and cite their sources.
Nox4 inhibition attenuates HFpEF-like remodeling in this model; leaves open clinical translation to AF-HFpEF.
Heart failure with preserved ejection fraction (HFpEF) commonly coexists with atrial fibrillation (AF), but shared mechanisms remain unclear. In this study, we hypothesized that Pitx2, a transcription factor located near the strongest genetic locus associated with AF in humans, increases susceptibility to HFpEF-like remodeling. We also sought to understand pathways that might be central to this increased risk. Male and female Pitx2+/− mice and wild-type littermates received 3-week subcutaneous osmotic pump infusion of saline or angiotensin II (Ang II; 500 ng/kg/min). Cardiac structure and function were assessed by echocardiography and catheterization, and functional capacity by exercise treadmill. RNA transcriptomic profiling was performed to identify candidate pathways. In a separate cohort, Ang II–treated mice were randomized to oral GKT136901 (30 mg/kg/day) or vehicle during infusion. After Ang II infusion, Pitx2+/− mice developed exaggerated HFpEF-like changes, including greater left ventricular hypertrophy, left atrial enlargement, diastolic dysfunction, elevated left ventricular end-diastolic pressure, and reduced treadmill performance. RNA-seq showed enrichment of metabolic and stress-response pathways with selective upregulation of Nox4, confirmed by RT-qPCR. GKT136901 attenuated structural remodeling, diastolic dysfunction indices, elevated filling pressures, and cardiomyocyte hypertrophy, but did not improve endurance. These findings implicate redox signaling, including Nox4, in AF genetic susceptibility–HFpEF interactions.
No takes yet. Share an insight, caveat, or question.
Gardner et al. (2026) conducted an RCT in Heart failure with preserved ejection fraction (HFpEF). GKT136901 vs. Vehicle was evaluated on Cardiac structural remodeling, diastolic dysfunction indices, elevated filling pressures, and cardiomyocyte hypertrophy. Oral GKT136901 attenuated structural remodeling, diastolic dysfunction, elevated filling pressures, and cardiomyocyte hypertrophy in Ang II-infused Pitx2+/- mice.
Synapse has enriched 10 related papers. Consider them for comparative context: